Clinical trials: Major Depression Disorders
Major Depressive Disorder (MDD)
Retrospective TMS Therapy for Adults With MDD
Examine change in the magnitude of antidepressant effects as a function of number of TMS sessions and to determine whether extended treatment courses, beyond 30 and beyond 36 TMS sessions, result in improved efficacy.
- Trial name
- NCT05541302
- Testing
- TMS
- Volunteers
- 6,456 people
- Sponsor
- Neuronetics
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
Treatment of Major Depressive Disorder in the UK Using TMS Therapy
The major objective of this observational study is to describe clinical outcomes of patients in the UK receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.
- Trial name
- NCT04217837
- Testing
- Transcranial Magnetic Stimulator
- Where
- United Kingdom
- Sponsor
- Neuronetics
Depression, Anxiety
Preoperative Anxiety and Depression Among Older Chinese Patients
A multicenter, cross-sectional study to characterize the clinical profiles of the Chinese elderly population and to determine the prevalence of preoperative anxiety and depression.
- Conditions
- Depression, Anxiety, Elderly Patients, Non-cardiac Major Surgery
- Trial name
- NCT07744295
- Volunteers
- 8,000 people
- Sponsor
- Chinese PLA General Hospital
Treatment Resistant Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major…
- Trial name
- NCT06524830
- Testing
- VLS-01-203 BU
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 142 people
- Sponsor
- atai Therapeutics, Inc.
Mood Disorders, Major Depressive Disorder
Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Mood disorders are associated with significant financial and health costs for the United States, partially due to cognitive problems in these patients that can worsen disease course and impair treatment response.
- Conditions
- Mood Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar Disorder II
- Trial name
- UnMASCK (NCT04358900)
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Major Depressive Disorder, Chronic Major Depression, Recurrent
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective…
- Trial name
- Re-EMBARC (NCT05892744)
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas at Austin
Resistant Major Depressive Disorder
DBS in Treatment Resistant Major Depression
This study aims at assessing efficacy and safety of DBS for treatment of patients suffering from resistant major depression, by means of a random, controlled and crossed study.
- Trial name
- NCT01268137
- Testing
- Deep Brain Stimulation
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Major Depressive Disorder
Tracking Response to Antidepressants in Advance of Investigational Trials, Relapse Study
TRAIT-RS is an observational study to evaluate ongoing treatment response stability to standard of care antidepressant treatments (ADTs) among individuals who met criteria for Major Depressive Disorder (MDD) and completed the…
- Trial name
- TRAIT-RS (NCT04933630)
- Testing
- FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Adams Clinical
Major Depressive Disorder
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India
- Trial name
- NCT04288895
- Testing
- Vortioxetine
- Where
- 24 sites in India
- Volunteers
- 400 people
- Sponsor
- H. Lundbeck A/S
Major Depression
Duke Conte Center for the Neuroscience of Depression in Late Life
The proposed Silvio O. Conte Center for Neuroscience of Depression will focus on understanding the neurobiological mechanism of depression. A total of 5 projects are proposed. The center is focused on a single hypothesis.
- Trial name
- NCT00576875
- Where
- United States
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Duke University
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depression
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.
- Trial name
- NCT00532480
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Major Depressive Disorder
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
- Trial name
- NCT00742573
- Testing
- Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder in Patients Taking PrEP
Mental Health and PreP
According to ANSM, by June 2023, almost 85,000 people living in France had initiated medical monitoring for HIV PrEP since 2016.
- Trial name
- SAM-P (NCT06944691)
- Testing
- Major depressive disorder scale
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy…
- Trial name
- NCT02951988
- Testing
- Rapastinel
- Where
- 137 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
Major Depressive Disorder
Electroconvulsive Therapy Amplitude Titration
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
- Trial name
- NCT04621786
- Testing
- Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of New Mexico
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.